APO RESEARCH · REPORT
Gastroparesis Drugs
Medications are used to try to help reduce symptoms of gastroparesis. The drug categories commonly used are prokinetic (promotility) agents and antiemetic agents.
Product & engineering
Understand the product.
Medications are used to try to help reduce symptoms of gastroparesis. The drug categories commonly used are prokinetic (promotility) agents and antiemetic agents.
Selected research
Market Structure
Global Gastroparesis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
Medications are used to try to help reduce symptoms of gastroparesis. The drug categories commonly used are prokinetic (promotility) agents and antiemetic agents.
North America is the largest consumer of Gastroparesis Drugs in global market.The second place is Europe, following North America.
Market is not concentrated. Sumitomo, Cadila Pharmaceuticals, Sanofi, Teva and Johnson & Johnsonare the leaders of the industry, and hold the key technologies and patent, with high-end customers.
Read the full market overview
This report provides an overview of the global Gastroparesis Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Gastroparesis Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Gastroparesis Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Gastroparesis Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Gastroparesis Drugs Segment by Company
Sumitomo
Cadila Pharmaceuticals
Sanofi
Teva
Johnson & Johnson
Pfizer
Kyowa Kirin Pharmaceuticals
Hanmi Pharm
Ani Pharmaceuticals
Gastroparesis Drugs Segment by Type
Prokinetic Agents
Antiemetic Agents
Others
Gastroparesis Drugs Segment by Application
Diabetic Gastroparesis
Idiopathic Gastroparesis
Gastroparesis Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastroparesis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gastroparesis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastroparesis Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Gastroparesis Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Gastroparesis Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Gastroparesis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Gastroparesis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Prokinetic Agents
- Antiemetic Agents
- Others
Applications
- Diabetic Gastroparesis
- Idiopathic Gastroparesis
Companies covered
- Sumitomo
- Cadila Pharmaceuticals
- Sanofi
- Teva
- Johnson & Johnson
- Pfizer
- Kyowa Kirin Pharmaceuticals
- Hanmi Pharm
- Ani Pharmaceuticals
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Gastroparesis Drugs Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Gastroparesis Drugs Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Gastroparesis Drugs Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Gastroparesis Drugs Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Gastroparesis Drugs Market Dynamics
- 2.1 Gastroparesis Drugs Industry Trends
- 2.2 Gastroparesis Drugs Industry Drivers
- 2.3 Gastroparesis Drugs Industry Opportunities and Challenges
- 2.4 Gastroparesis Drugs Industry Restraints
3 Gastroparesis Drugs Market by Manufacturers
- 3.1 Global Gastroparesis Drugs Revenue by Manufacturers (2021-2026)
- 3.2 Global Gastroparesis Drugs Sales by Manufacturers (2021-2026)
- 3.3 Global Gastroparesis Drugs Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Gastroparesis Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Gastroparesis Drugs Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Gastroparesis Drugs Manufacturers, Product Type & Application
- 3.7 Global Gastroparesis Drugs Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Gastroparesis Drugs Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Gastroparesis Drugs Players Market Share by Revenue in 2025
- 3.8.3 2025 Gastroparesis Drugs Tier 1, Tier 2, and Tier 3
4 Gastroparesis Drugs Market by Type
- 4.1 Gastroparesis Drugs Type Introduction
- 4.1.1 Prokinetic Agents
- 4.1.2 Antiemetic Agents
- 4.1.3 Others
- 4.2 Global Gastroparesis Drugs Sales by Type
- 4.2.1 Global Gastroparesis Drugs Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Gastroparesis Drugs Sales by Type (2021-2032)
- 4.2.3 Global Gastroparesis Drugs Sales Market Share by Type (2021-2032)
- 4.3 Global Gastroparesis Drugs Revenue by Type
- 4.3.1 Global Gastroparesis Drugs Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Gastroparesis Drugs Revenue by Type (2021-2032)
- 4.3.3 Global Gastroparesis Drugs Revenue Market Share by Type (2021-2032)
5 Gastroparesis Drugs Market by Application
- 5.1 Gastroparesis Drugs Application Introduction
- 5.1.1 Diabetic Gastroparesis
- 5.1.2 Idiopathic Gastroparesis
- 5.2 Global Gastroparesis Drugs Sales by Application
- 5.2.1 Global Gastroparesis Drugs Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Gastroparesis Drugs Sales by Application (2021-2032)
- 5.2.3 Global Gastroparesis Drugs Sales Market Share by Application (2021-2032)
- 5.3 Global Gastroparesis Drugs Revenue by Application
- 5.3.1 Global Gastroparesis Drugs Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Gastroparesis Drugs Revenue by Application (2021-2032)
- 5.3.3 Global Gastroparesis Drugs Revenue Market Share by Application (2021-2032)
6 Global Gastroparesis Drugs Sales by Region
- 6.1 Global Gastroparesis Drugs Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Gastroparesis Drugs Sales by Region (2021-2032)
- 6.2.1 Global Gastroparesis Drugs Sales by Region (2021-2026)
- 6.2.2 Global Gastroparesis Drugs Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Gastroparesis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Gastroparesis Drugs Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Gastroparesis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Gastroparesis Drugs Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Gastroparesis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Gastroparesis Drugs Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Gastroparesis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Gastroparesis Drugs Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Gastroparesis Drugs Revenue by Region
- 7.1 Global Gastroparesis Drugs Revenue by Region
- 7.1.1 Global Gastroparesis Drugs Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Gastroparesis Drugs Revenue by Region (2021-2026)
- 7.1.3 Global Gastroparesis Drugs Revenue by Region (2027-2032)
- 7.1.4 Global Gastroparesis Drugs Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Gastroparesis Drugs Revenue (2021-2032)
- 7.2.2 North America Gastroparesis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Gastroparesis Drugs Revenue (2021-2032)
- 7.3.2 Europe Gastroparesis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Gastroparesis Drugs Revenue (2021-2032)
- 7.4.2 Asia-Pacific Gastroparesis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Gastroparesis Drugs Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Gastroparesis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Sumitomo
- 8.1.1 Sumitomo Company Information
- 8.1.2 Sumitomo Business Overview
- 8.1.3 Sumitomo Gastroparesis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Sumitomo Gastroparesis Drugs Product Portfolio
- 8.1.5 Sumitomo Recent Developments
- 8.2 Cadila Pharmaceuticals
- 8.2.1 Cadila Pharmaceuticals Company Information
- 8.2.2 Cadila Pharmaceuticals Business Overview
- 8.2.3 Cadila Pharmaceuticals Gastroparesis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Cadila Pharmaceuticals Gastroparesis Drugs Product Portfolio
- 8.2.5 Cadila Pharmaceuticals Recent Developments
- 8.3 Sanofi
- 8.3.1 Sanofi Company Information
- 8.3.2 Sanofi Business Overview
- 8.3.3 Sanofi Gastroparesis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Sanofi Gastroparesis Drugs Product Portfolio
- 8.3.5 Sanofi Recent Developments
- 8.4 Teva
- 8.4.1 Teva Company Information
- 8.4.2 Teva Business Overview
- 8.4.3 Teva Gastroparesis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Teva Gastroparesis Drugs Product Portfolio
- 8.4.5 Teva Recent Developments
- 8.5 Johnson & Johnson
- 8.5.1 Johnson & Johnson Company Information
- 8.5.2 Johnson & Johnson Business Overview
- 8.5.3 Johnson & Johnson Gastroparesis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Johnson & Johnson Gastroparesis Drugs Product Portfolio
- 8.5.5 Johnson & Johnson Recent Developments
- 8.6 Pfizer
- 8.6.1 Pfizer Company Information
- 8.6.2 Pfizer Business Overview
- 8.6.3 Pfizer Gastroparesis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Pfizer Gastroparesis Drugs Product Portfolio
- 8.6.5 Pfizer Recent Developments
- 8.7 Kyowa Kirin Pharmaceuticals
- 8.7.1 Kyowa Kirin Pharmaceuticals Company Information
- 8.7.2 Kyowa Kirin Pharmaceuticals Business Overview
- 8.7.3 Kyowa Kirin Pharmaceuticals Gastroparesis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Kyowa Kirin Pharmaceuticals Gastroparesis Drugs Product Portfolio
- 8.7.5 Kyowa Kirin Pharmaceuticals Recent Developments
- 8.8 Hanmi Pharm
- 8.8.1 Hanmi Pharm Company Information
- 8.8.2 Hanmi Pharm Business Overview
- 8.8.3 Hanmi Pharm Gastroparesis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Hanmi Pharm Gastroparesis Drugs Product Portfolio
- 8.8.5 Hanmi Pharm Recent Developments
- 8.9 Ani Pharmaceuticals
- 8.9.1 Ani Pharmaceuticals Company Information
- 8.9.2 Ani Pharmaceuticals Business Overview
- 8.9.3 Ani Pharmaceuticals Gastroparesis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Ani Pharmaceuticals Gastroparesis Drugs Product Portfolio
- 8.9.5 Ani Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Gastroparesis Drugs Value Chain Analysis
- 9.1.1 Gastroparesis Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Gastroparesis Drugs Production Mode & Process
- 9.2 Gastroparesis Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Gastroparesis Drugs Distributors
- 9.2.3 Gastroparesis Drugs Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst